期刊
CANCER CELL
卷 27, 期 3, 页码 382-396出版社
CELL PRESS
DOI: 10.1016/j.ccell.2015.02.007
关键词
-
资金
- Spanish Ministry of Economy and Competitiveness [SAF2012-36199]
- La Fundacio la Marato de TV3
- Spanish National Institute of Bioinformatics (INB)
- FPI fellowship
- People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union [600388]
- Agency of Competitiveness for Companies of the Government of Catalonia, ACCIO
- Ramon y Cajal contract
- ICREA Funding Source: Custom
Large efforts dedicated to detect somatic alterations across tumor genomes/exomes are expected to produce significant improvements in precision cancer medicine. However, high inter-tumor heterogeneity is a major obstacle to developing and applying therapeutic targeted agents to treat most cancer patients. Here, we offer a comprehensive assessment of the scope of targeted therapeutic agents in a large pan-cancer cohort. We developed an in silico prescription strategy based on identification of the driver alterations in each tumor and their druggability options. Although relatively few tumors are tractable by approved agents following clinical guidelines (5.9%), up to 40.2% could benefit from different repurposing options, and up to 73.3% considering treatments currently under clinical investigation. We also identified 80 therapeutically targetable cancer genes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据